Heart Test Laboratories
HSCS
4 hedge funds and large institutions have $83K invested in Heart Test Laboratories in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$45.2K |
| 2 |
Jane Street
New York
|
+$28.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.31K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.29K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $44K | +$45.2K | +234 | New |
|
|
2
Jane Street
New York
| $28K | +$28.8K | +149 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $8K | +$8.31K | +43 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3K | +$3.29K | +17 | New |
|
HSCS Hedge Fund Activity: Q2 2022 in Review
4 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Heart Test Laboratories (HSCS) for Q2 2022, worth a combined $83K.
Buyers outnumbered sellers: 4 funds opened new HSCS positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $45.2K.
- 4 institutional investors held Heart Test Laboratories (HSCS) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $83K of Heart Test Laboratories stock for Q2 2022.
- 4 funds opened new Heart Test Laboratories positions in Q2 2022 and 0 closed out, a net change of +4 holders.
- The largest Heart Test Laboratories buyer in Q2 2022 was Citadel Advisors, an estimated $45.2K added.
Based on aggregated 13F filings for Q2 2022.